HC Wainwright Reiterates “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Posted by Brenda Bartman on Sep 25th, 2026

Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 74.98% from the stock’s previous close.

A number of other brokerages also recently issued reports on TLX. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Telix Pharmaceuticals presently has an average rating of “Buy” and an average target price of $20.50.

Check Out Our Latest Stock Analysis on TLX

Telix Pharmaceuticals Price Performance

Shares of NASDAQ:TLX traded up $0.12 during trading on Friday, hitting $11.43. 320,922 shares of the company’s stock traded hands, compared to its average volume of 221,458. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. The company has a 50-day moving average price of $11.33 and a 200-day moving average price of $10.47. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $13.11.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares in the last quarter. XY Capital Ltd bought a new position in Telix Pharmaceuticals in the 1st quarter worth approximately $120,000. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $1,731,000. Private Advisor Group LLC grew its holdings in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after buying an additional 39,400 shares in the last quarter.

Telix Pharmaceuticals Company Profile

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.